Worldquant Millennium Advisors LLC Invests $4.96 Million in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Worldquant Millennium Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 224,974 shares of the company's stock, valued at approximately $4,958,000.

Several other institutional investors have also modified their holdings of TEVA. FMR LLC raised its holdings in shares of Teva Pharmaceutical Industries by 30.7% during the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after acquiring an additional 19,242,468 shares during the period. Duquesne Family Office LLC raised its holdings in shares of Teva Pharmaceutical Industries by 530.1% during the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock worth $198,303,000 after acquiring an additional 7,569,450 shares during the period. Clal Insurance Enterprises Holdings Ltd raised its holdings in shares of Teva Pharmaceutical Industries by 12.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after acquiring an additional 4,418,961 shares during the period. Todd Asset Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth $58,243,000. Finally, Marshall Wace LLP raised its holdings in shares of Teva Pharmaceutical Industries by 87.8% during the 4th quarter. Marshall Wace LLP now owns 5,155,402 shares of the company's stock worth $113,625,000 after acquiring an additional 2,410,420 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, April 23rd. UBS Group reduced their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Finally, JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $21.00 to $23.00 in a report on Monday, May 12th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $24.43.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $16.58 on Thursday. The company has a market cap of $18.79 billion, a P/E ratio of -11.43, a P/E/G ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The stock has a 50-day moving average of $15.37 and a two-hundred day moving average of $17.38. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. The company had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Teva Pharmaceutical Industries's revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.48 EPS. As a group, analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.